ECSP14013305A - Moduladores selectivos del receptor andrógeno - Google Patents

Moduladores selectivos del receptor andrógeno

Info

Publication number
ECSP14013305A
ECSP14013305A ECSP14013305A ECSP14013305A EC SP14013305 A ECSP14013305 A EC SP14013305A EC SP14013305 A ECSP14013305 A EC SP14013305A EC SP14013305 A ECSP14013305 A EC SP14013305A
Authority
EC
Ecuador
Prior art keywords
selective modulators
androgen
receiver selective
androgen receiver
modulators
Prior art date
Application number
Other languages
English (en)
Spanish (es)
Inventor
Venkatesh Gary Krishnan
Prabhakar Kondaji Jadhav
Donald Paul Matthews
Gregory Alan Stephenson
Jonathan Edward Green
Ashraf Saeed
Original Assignee
Lilly Co Eli
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=47046879&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=ECSP14013305(A) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Lilly Co Eli filed Critical Lilly Co Eli
Publication of ECSP14013305A publication Critical patent/ECSP14013305A/es

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00Drugs for skeletal disorders
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00Drugs for disorders of the muscular or neuromuscular system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00Drugs for disorders of the muscular or neuromuscular system
    • A61P21/06Anabolic agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00Drugs for disorders of the endocrine system
    • A61P5/24Drugs for disorders of the endocrine system of the sex hormones
    • A61P5/26Androgens
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07CACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C255/00Carboxylic acid nitriles
    • C07C255/49Carboxylic acid nitriles having cyano groups bound to carbon atoms of six-membered aromatic rings of a carbon skeleton
    • C07C255/58Carboxylic acid nitriles having cyano groups bound to carbon atoms of six-membered aromatic rings of a carbon skeleton containing cyano groups and singly-bound nitrogen atoms, not being further bound to other hetero atoms, bound to the carbon skeleton
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D307/00Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom
    • C07D307/02Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom not condensed with other rings
    • C07D307/04Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom not condensed with other rings having no double bonds between ring members or between ring members and non-ring members
    • C07D307/18Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom not condensed with other rings having no double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D307/22Nitrogen atoms not forming part of a nitro radical
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D309/00Heterocyclic compounds containing six-membered rings having one oxygen atom as the only ring hetero atom, not condensed with other rings
    • C07D309/02Heterocyclic compounds containing six-membered rings having one oxygen atom as the only ring hetero atom, not condensed with other rings having no double bonds between ring members or between ring members and non-ring members
    • C07D309/08Heterocyclic compounds containing six-membered rings having one oxygen atom as the only ring hetero atom, not condensed with other rings having no double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D309/14Nitrogen atoms not forming part of a nitro radical
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07BGENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
    • C07B2200/00Indexing scheme relating to specific properties of organic compounds
    • C07B2200/07Optical isomers
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07BGENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
    • C07B2200/00Indexing scheme relating to specific properties of organic compounds
    • C07B2200/13Crystalline forms, e.g. polymorphs
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07CACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C2601/00Systems containing only non-condensed rings
    • C07C2601/06Systems containing only non-condensed rings with a five-membered ring
    • C07C2601/08Systems containing only non-condensed rings with a five-membered ring the ring being saturated
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07CACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C2601/00Systems containing only non-condensed rings
    • C07C2601/12Systems containing only non-condensed rings with a six-membered ring
    • C07C2601/14The ring being saturated

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Engineering & Computer Science (AREA)
  • Public Health (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Endocrinology (AREA)
  • Neurology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Diabetes (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicinal Preparation (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
ECSP14013305 2011-10-13 2014-04-11 Moduladores selectivos del receptor andrógeno ECSP14013305A (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US201161546711P 2011-10-13 2011-10-13

Publications (1)

Publication Number Publication Date
ECSP14013305A true ECSP14013305A (es) 2014-05-31

Family

ID=47046879

Family Applications (1)

Application Number Title Priority Date Filing Date
ECSP14013305 ECSP14013305A (es) 2011-10-13 2014-04-11 Moduladores selectivos del receptor andrógeno

Country Status (28)

Country Link
US (1) US8658693B2 (show.php)
EP (1) EP2766350B1 (show.php)
JP (1) JP6002228B2 (show.php)
KR (1) KR20140067102A (show.php)
CN (1) CN103842348B (show.php)
AP (1) AP2014007548A0 (show.php)
AR (1) AR088082A1 (show.php)
AU (1) AU2012321113B2 (show.php)
BR (1) BR112014008668A2 (show.php)
CA (1) CA2847889A1 (show.php)
CL (1) CL2014000895A1 (show.php)
CO (1) CO6910195A2 (show.php)
CR (1) CR20140156A (show.php)
DO (1) DOP2014000075A (show.php)
EA (1) EA201490519A1 (show.php)
EC (1) ECSP14013305A (show.php)
ES (1) ES2626820T3 (show.php)
GT (1) GT201400067A (show.php)
IL (1) IL231440A0 (show.php)
MX (1) MX2014004558A (show.php)
PE (1) PE20141669A1 (show.php)
PH (1) PH12014500808A1 (show.php)
PL (1) PL2766350T3 (show.php)
PT (1) PT2766350T (show.php)
SG (1) SG11201401794YA (show.php)
TN (1) TN2014000136A1 (show.php)
TW (1) TWI449686B (show.php)
WO (1) WO2013055577A1 (show.php)

Families Citing this family (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20140045856A1 (en) 2012-07-31 2014-02-13 Boehringer Ingelheim International Gmbh 4-Methyl-2,3,5,9,9b-pentaaza-cyclopenta[a]naphthalenes
TW201534586A (zh) * 2013-06-11 2015-09-16 Orion Corp 新穎cyp17抑制劑/抗雄激素劑
EP3077383B1 (en) 2013-12-04 2018-08-22 Evotec International GmbH Sulfoximine substituted quinazolines for pharmaceutical compositions
US9682960B2 (en) 2013-12-19 2017-06-20 Endorecherche, Inc. Non-steroidal antiandrogens and selective androgen receptor modulators with a pyridyl moiety
WO2015169677A1 (en) 2014-05-07 2015-11-12 Boehringer Ingelheim International Gmbh Sulfoximine substituted quinazolines for pharmaceutical compositions
HUE055978T2 (hu) 2016-08-15 2022-01-28 Pfizer Piridopirimidinon CDK2/4/6 inhibitorok
ES2824495T3 (es) 2016-09-02 2021-05-12 Suven Life Sciences Ltd Moduladores alostéricos positivos del receptor muscarínico M1
EP3684761A1 (en) 2017-09-18 2020-07-29 Basf Se Substituted trifluoromethyloxadiazoles for combating phytopathogenic fungi
CN115955979B (zh) * 2020-06-24 2025-12-05 新基公司 Cereblon结合化合物、其组合物及其用于治疗的方法
WO2025104624A1 (en) * 2023-11-14 2025-05-22 Pfizer Inc. Synthesis of 1,5-anhydro-3-({5-chloro-4-[4-fluoro-2-(2-hydroxypropan-2-yl)-1-(propan-2-yl)-1h-benzimidazol-6-yl]pyrimidin-2-yl}amino)-2,3-dideoxy-d-threo-pentitol

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3594405A (en) * 1968-05-17 1971-07-20 Du Pont Substituted pyranyl anilines as plant growth modifiers
DE60208630T2 (de) * 2001-05-11 2006-08-17 Pfizer Products Inc., Groton Thiazolderivate und ihre Verwendung als cdk-Inhibitoren
US8519158B2 (en) * 2004-03-12 2013-08-27 Ligand Pharmaceuticals Incorporated Androgen receptor modulator compounds and methods
CN101175747B (zh) * 2005-05-13 2011-06-22 伊莱利利公司 作为选择性雄激素受体调节剂的取代的n-芳基吡咯烷化合物
US8106190B2 (en) * 2005-11-30 2012-01-31 Astellas Pharma Inc. 2-aminobenzamide derivatives
CA2684240A1 (en) * 2007-04-16 2008-10-30 Serenex, Inc. Tetrahydroindole and tetrahydroindazole derivatives
CA2702777A1 (en) * 2007-10-19 2009-04-23 Michelle Letendre-Hedlund Methods of identifying environmentally friendly businesses or individuals
EP2260028B1 (en) * 2008-02-22 2014-05-07 Radius Health, Inc. Selective androgen receptor modulators

Also Published As

Publication number Publication date
EP2766350B1 (en) 2017-04-05
CN103842348B (zh) 2015-08-19
TWI449686B (zh) 2014-08-21
CN103842348A (zh) 2014-06-04
ES2626820T3 (es) 2017-07-26
TN2014000136A1 (en) 2015-07-01
JP6002228B2 (ja) 2016-10-05
AU2012321113B2 (en) 2015-07-09
KR20140067102A (ko) 2014-06-03
PE20141669A1 (es) 2014-11-08
MX2014004558A (es) 2014-08-01
CA2847889A1 (en) 2013-04-18
EA201490519A1 (ru) 2014-09-30
CO6910195A2 (es) 2014-03-31
PL2766350T3 (pl) 2017-08-31
AP2014007548A0 (en) 2014-03-31
US8658693B2 (en) 2014-02-25
IL231440A0 (en) 2014-04-30
GT201400067A (es) 2015-02-27
AR088082A1 (es) 2014-05-07
PT2766350T (pt) 2017-05-22
DOP2014000075A (es) 2014-06-01
EP2766350A1 (en) 2014-08-20
PH12014500808A1 (en) 2019-07-03
TW201329026A (zh) 2013-07-16
US20130217762A1 (en) 2013-08-22
JP2014530818A (ja) 2014-11-20
WO2013055577A1 (en) 2013-04-18
BR112014008668A2 (pt) 2017-04-25
SG11201401794YA (en) 2014-09-26
CL2014000895A1 (es) 2014-08-22
CR20140156A (es) 2014-05-16
AU2012321113A1 (en) 2014-03-27

Similar Documents

Publication Publication Date Title
ECSP14013305A (es) Moduladores selectivos del receptor andrógeno
CO7151521A2 (es) Anticuerpos anti-fcrn
CO7170179A2 (es) Moduladores del receptor de estrogeno y sus usos
GT201300196A (es) Moduladores del receptor de glucagón
CR20160184A (es) Piperidil-etil-pirimidina sustituido como inhibidor de ghrelin o-acil transferasa
ME03081B (me) Modulatora receptora androgena patentni zahtevi
CO7350623A2 (es) Agentes moduladores de autotaxina (atx)
BR112015008272A2 (pt) cápsula para preparação de bebidas
SMT201700009B (it) Modulatori del recettore x del fegato
UY33906A (es) Composiciones herbicidas que comprenden topramezona
UY34682A (es) Anticuerpos frente a los ligandos del receptor b1 de bradicinina.
SMT201600374B (it) Modulatori del recettore x del fegato
EP2911666A4 (en) MODULATORS OF A RESISTANT ANDROGEN RECEPTOR
HUE042370T2 (hu) Benzoxazinon-amidok mint mineralokortikoid-receptor modulátorok
HRP20181596T1 (hr) Tiazolopirimidinoni kao modulatori aktivnosti nmda receptora
CR20140124A (es) Metabolitos de transclomifeno y usos de los mismos
ME02996B (me) Indolkarb0niтrili као selekтivni modulatori receptora androgena
DK3145916T3 (da) Imidazolderivater som formylpeptidreceptormodulatorer
CO7111295A2 (es) Anticuerpo anti-rob04
EP2872339A4 (en) SCOREBOARD
CO6852071A2 (es) Moduladores alostéricos positivos del receptor de acetilcolina nicotínico
UY34595A (es) Composición farmacéutica de liberación prolongada de trimetazidina
CO6900142A2 (es) Derivados de etinilo como moduladores del receptor metatrópico de glutamato
CO7151505A2 (es) Formulación oral
DK3345899T3 (da) Benzofuran-2-sulfonamidderivater som kemokinreceptormodulatorer